Samda Biolab Co., Ltd. → Liminatus Pharma, Inc. LIMNW

Stake: — Shares: — Class: Common Stock , par value $0.0001 per share

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 20/100

Passive Schedule 13G filer baseline
Held by 1 tracked 13F institutional manager
Elevated short days-to-cover (44.7 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

2 13D/G filings on this issuer

1 other filing besides this one

Filer Track Record

1 filings by this filer

0 other filings in the data moat

Short Interest · settle 2026-09-30

DTC 44.69

6,614 shares short · 0.0% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $434

Point72 Asset Mgmt

Other 13D/G Filings on Liminatus Pharma, Inc.

Filed	Form	Filer	Stake	Shares
2026-07-14	SCHEDULE 13D/A	Valetudo Therapeutics LLC	14.30%	9,617,954	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →